BCIQ Profiles

Company Profile Report
1124 ECP resilience
BioCentury & Getty Images

Emerging Company Profile

Building Resilience into U.S. biomanufacturing

With more than $800M in cash, Resilience aims to streamline manufacturing services spanning preclinical development through commercialization

Resilience debuts with more than $800M to reduce manufacturing wait and lead times across multiple modalities. 

Nov 25, 2020 | 1:22 AM GMT

In addition to building manufacturing infrastructure across multiple modalities, Resilience plans to offer its clients standardized protocols and consulting services that could help cut down on production wait and lead times as well as

Read the full 843 word article

How to gain access

Continue reading with a
two-week free trial.